Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9

Purpose: Gene therapy has become a promising remedy to treat disease by modifying the person’s genes. The therapeutic potential of related tools such as CRISPR-Cas9 depends on the efficiency of delivery to the targeted cells. Numerous transfection reagents have been designed and lots of efforts have been devoted to develop carriers for this purpose. Therefore, the aim of the present study was to develop novel cholesterol-rich lipid-based nanoparticles to enhance transfection efficiency and serum stability. Materials and methods: We constructed two-, three- and four-component cationic liposomes (CLs) to evaluate the combined effect of cholesterol domain and DOPE (dioleoyl phosphatidylethanolamine), a fusogenic lipid, and the PEG (polyethylene glycol) moiety location inside or outside of the cholesterol domain on transfection efficiency and other properties of the particle. Lipoplex formation and pDNA (plasmid DNA) entrapment were assessed by gel retardation assay at different N/P ratios (3, 5, 7). Physicochemical characteristics, cytotoxicity, serum stability and endosomal escape capability of the lipoplexes were studied and transfection potential was measured by firefly luciferase assay. Next, HEK293 cell line stably expressing GFP was utilized to demonstrate the editing of a reporter through Cas9 and sgRNA plasmids delivery by the selected CL formula, which showed the highest transfection efficiency. Results: Among the designed CLs, the four-component formula [DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane)/DOPE/cholesterol/Chol-PEG (cholesterol-polyethylene glycol)] showed the highest rate of transfection at N/P 3. Finally, transfection of Cas9/sgRNA by this formulation at N/P 3 resulted in 39% gene-editing efficiency to knockout GFP reporter. The results also show that this CL with no cytotoxicity effect can totally protect the plasmids from enzymatic degradation in serum. Conclusion: The novel PEGylated cholesterol domain lipoplex providing serum stability, higher transfection efficiency and endosomal release can be used for in vivo Cas9/sgRNA delivery and other future gene-therapy applications.

[1]  S. Hosseinkhani,et al.  In vivo tumor gene delivery using novel peptideticles: pH‐responsive and ligand targeted core–shell nanoassembly , 2018, International journal of cancer.

[2]  Xiaoyuan Chen,et al.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. , 2018, Biomaterials.

[3]  Lennart Lindfors,et al.  Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles , 2018, Proceedings of the National Academy of Sciences.

[4]  A. Chaudhuri,et al.  A lipid-based cell penetrating nano-assembly for RNAi-mediated anti-angiogenic cancer therapy. , 2018, Chemical communications.

[5]  Jerilyn A Timlin,et al.  Delivering CRISPR: a review of the challenges and approaches , 2018, Drug delivery.

[6]  S. Hosseinkhani,et al.  Simultaneous Gene Delivery and Tracking through Preparation of Photo-Luminescent Nanoparticles Based on Graphene Quantum Dots and Chimeric Peptides , 2017, Scientific Reports.

[7]  Gang Bao,et al.  CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. , 2017, Chemical reviews.

[8]  Akshay Jain,et al.  Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery. , 2017, Molecular pharmaceutics.

[9]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.

[10]  S. Hosseinkhani,et al.  Development of novel recombinant biomimetic chimeric MPG-based peptide as nanocarriers for gene delivery: Imitation of a real cargo. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  Neville E. Sanjana,et al.  High-throughput functional genomics using CRISPR–Cas9 , 2015, Nature Reviews Genetics.

[12]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[13]  Bruno F B Silva,et al.  Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging. , 2014, Biomaterials.

[14]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[15]  Jayanta Bhattacharyya,et al.  Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[17]  S. Hosseinkhani,et al.  Lipid composition of cationic nanoliposomes implicate on transfection efficiency , 2013, Journal of liposome research.

[18]  H. Kasukawa,et al.  Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods. , 2012, Biochimica et biophysica acta.

[19]  Nouri Nayerossadat,et al.  Viral and nonviral delivery systems for gene delivery , 2012, Advanced biomedical research.

[20]  R. Barrangou,et al.  CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. , 2011, Annual review of genetics.

[21]  S. Hosseinkhani,et al.  Preparation, characterization, and efficient transfection of cationic liposomes and nanomagnetic cationic liposomes , 2011, International journal of nanomedicine.

[22]  Yuan Yuan,et al.  In vitro cytotoxicity and induction of apoptosis by silica nanoparticles in human HepG2 hepatoma cells , 2011, International journal of nanomedicine.

[23]  T. Anchordoquy,et al.  The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. , 2011, Therapeutic delivery.

[24]  T. Anchordoquy,et al.  Cholesterol domains in cationic lipid/DNA complexes improve transfection. , 2008, Biochimica et biophysica acta.

[25]  J. Byrd,et al.  Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. , 2007, Journal of pharmaceutical sciences.

[26]  S. D. De Smedt,et al.  Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Y. Barenholz,et al.  Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. , 2005, Chemistry and physics of lipids.

[28]  F. Szoka,et al.  Low‐pH‐sensitive poly(ethylene glycol) (PEG)‐stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery , 2005, The journal of gene medicine.

[29]  T. Anchordoquy,et al.  The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. , 2004, Biochimica et biophysica acta.

[30]  D. Hoekstra,et al.  Molecular Shape of the Cationic Lipid Controls the Structure of Cationic Lipid/Dioleylphosphatidylethanolamine-DNA Complexes and the Efficiency of Gene Delivery* , 2001, The Journal of Biological Chemistry.

[31]  Akshay Jain,et al.  Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[32]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.

[33]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[34]  Murali Ramamoorth,et al.  Non viral vectors in gene therapy- an overview. , 2015, Journal of clinical and diagnostic research : JCDR.

[35]  H Fessi,et al.  Gene therapy and DNA delivery systems. , 2014, International journal of pharmaceutics.

[36]  M. Sands.  AAV-mediated liver-directed gene therapy. , 2011, Methods in molecular biology.

[37]  E. Wisse,et al.  The role of liver sinusoidal cells in hepatocyte-directed gene transfer. , 2010, The American journal of pathology.

[38]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.